Patients receiving dupilumab for atopic dermatitis may be at increased risk of developing conjunctivitis.

This article provides clinical guidance on the recognition and management of dupilumab-associated conjunctivitis.

The approach to management involves distinguishing between mild and moderate-to-severe conjunctivitis to tailor therapy appropriately, and co-management with ophthalmology is often required.